RS55245B1 - Helatni kompleksi oligonukleotida - Google Patents

Helatni kompleksi oligonukleotida

Info

Publication number
RS55245B1
RS55245B1 RS20160869A RSP20160869A RS55245B1 RS 55245 B1 RS55245 B1 RS 55245B1 RS 20160869 A RS20160869 A RS 20160869A RS P20160869 A RSP20160869 A RS P20160869A RS 55245 B1 RS55245 B1 RS 55245B1
Authority
RS
Serbia
Prior art keywords
rep
oligonucleotide
calcium
chelate
formation
Prior art date
Application number
RS20160869A
Other languages
English (en)
Serbian (sr)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS55245(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of RS55245B1 publication Critical patent/RS55245B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
RS20160869A 2010-08-20 2011-08-18 Helatni kompleksi oligonukleotida RS55245B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes
EP11817618.9A EP2605794B1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (1)

Publication Number Publication Date
RS55245B1 true RS55245B1 (sr) 2017-02-28

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160869A RS55245B1 (sr) 2010-08-20 2011-08-18 Helatni kompleksi oligonukleotida

Country Status (35)

Country Link
US (2) US8513211B2 (enExample)
EP (1) EP2605794B1 (enExample)
JP (1) JP5775581B2 (enExample)
KR (3) KR101606495B1 (enExample)
CN (2) CN103052405B (enExample)
AU (1) AU2011291401B2 (enExample)
BR (1) BR112013003875B1 (enExample)
CA (2) CA2855690C (enExample)
CL (1) CL2013000445A1 (enExample)
CO (1) CO6670525A2 (enExample)
CR (1) CR20130069A (enExample)
CU (1) CU20130022A7 (enExample)
CY (1) CY1118207T1 (enExample)
DK (1) DK2605794T3 (enExample)
DO (1) DOP2013000041A (enExample)
EA (1) EA026660B1 (enExample)
EC (1) ECSP13012449A (enExample)
ES (1) ES2598556T3 (enExample)
GT (1) GT201300040A (enExample)
HR (1) HRP20161333T1 (enExample)
HU (1) HUE029521T2 (enExample)
IL (1) IL224237A (enExample)
LT (1) LT2605794T (enExample)
MX (1) MX340294B (enExample)
MY (1) MY160961A (enExample)
NZ (1) NZ606364A (enExample)
PH (1) PH12013500192B1 (enExample)
PL (1) PL2605794T3 (enExample)
PT (1) PT2605794T (enExample)
RS (1) RS55245B1 (enExample)
SG (1) SG187165A1 (enExample)
SI (1) SI2605794T1 (enExample)
SM (1) SMT201600370B (enExample)
WO (1) WO2012021985A1 (enExample)
ZA (1) ZA201300497B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP3228712A1 (en) 2012-04-23 2017-10-11 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
PT2846839T (pt) * 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
BR112014033004B1 (pt) * 2012-07-03 2021-10-19 Biomarin Technologies B.V. Oligonucleotídeo para tratamento de pacientes com distrofia muscular
IN2015DN01087A (enExample) 2012-08-30 2015-06-26 Replicor Inc
CN113750112A (zh) 2014-07-10 2021-12-07 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
MX383293B (es) * 2015-04-23 2025-03-13 Geron Corp Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005023829A1 (ja) * 2003-09-02 2005-03-17 Japan Science And Technology Agency 金属錯体型核酸
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
CA2613101A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
PH12013500192A1 (enExample) 2013-03-11
US20120046348A1 (en) 2012-02-23
CL2013000445A1 (es) 2013-11-22
SG187165A1 (en) 2013-02-28
CN103052405B (zh) 2015-11-25
EA026660B1 (ru) 2017-05-31
BR112013003875B1 (pt) 2021-10-05
CR20130069A (es) 2013-09-20
CO6670525A2 (es) 2013-05-15
CN103052405A (zh) 2013-04-17
HRP20161333T1 (hr) 2016-12-02
CA2855690A1 (en) 2012-02-23
PL2605794T3 (pl) 2017-01-31
CA2806616A1 (en) 2012-02-23
SMT201600370B (it) 2016-11-10
MX340294B (es) 2016-07-04
US8716259B2 (en) 2014-05-06
KR20150039873A (ko) 2015-04-13
WO2012021985A1 (en) 2012-02-23
EP2605794B1 (en) 2016-07-20
LT2605794T (lt) 2016-10-25
MX2013001668A (es) 2013-07-22
MY160961A (en) 2017-03-31
ECSP13012449A (es) 2013-04-30
KR101606495B1 (ko) 2016-03-28
PT2605794T (pt) 2016-10-25
DOP2013000041A (es) 2017-12-15
HK1184058A1 (zh) 2014-01-17
JP2013536195A (ja) 2013-09-19
CU20130022A7 (es) 2013-04-19
US20130296410A1 (en) 2013-11-07
IL224237A (en) 2015-09-24
DK2605794T3 (en) 2016-10-24
HUE029521T2 (en) 2017-03-28
EA201300259A1 (ru) 2013-12-30
CN103768086A (zh) 2014-05-07
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
HK1198123A1 (en) 2015-03-13
US8513211B2 (en) 2013-08-20
EP2605794A4 (en) 2014-07-02
EP2605794A1 (en) 2013-06-26
KR20150082685A (ko) 2015-07-15
BR112013003875A2 (en) 2018-03-13
GT201300040A (es) 2014-09-02
KR20130099067A (ko) 2013-09-05
JP5775581B2 (ja) 2015-09-09
AU2011291401A1 (en) 2013-01-10
CA2855690C (en) 2015-08-25
PH12013500192B1 (en) 2018-11-23
CN103768086B (zh) 2015-10-14
SI2605794T1 (sl) 2017-01-31
ZA201300497B (en) 2013-09-25
CA2806616C (en) 2015-08-11
NZ606364A (en) 2014-12-24
AU2011291401B2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
RS55245B1 (sr) Helatni kompleksi oligonukleotida
JP6294308B2 (ja) オリゴヌクレオチドキレート錯体方法
RS62030B1 (sr) Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
HK1184058B (en) Oligonucleotide chelate complexes
HK1198123B (en) The use of oligonucleotide chelate complexes